Emerging treatment landscape for Guillain-Barré Syndrome (GBS): what’s new?
- 10 July 2024
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 33 (9) , 881-886
Abstract
Introduction: Guillain-Barr & eacute; syndrome (GBS) is a monophasic immune neuropathic disorder characterized by acute paralysis. A significant portion of patients are left with residual deficits, which presents a considerable global healthcare challenge. The precise mechanisms underlying GBS pathogenesis are not fully elucidated. Recent studies have focused on postinfectious molecular mimicry and identified involvement of IgG autoantibodies and innate immune effectors in GBS. Intravenous immunoglobulins (IVIg) and plasma exchange (PE) are two established evidence-based immunomodulatory treatments for GBS, but a significant proportion of GBS patients fails to respond adequately to either therapy. This emphasizes an urgent need for novel and more potent treatments. Areas covered: We discuss novel immunomodulatory therapies presently at different phases of preclinical and clinical investigation. Some drugs in development target pathophysiologic mechanisms such as IgG autoantibody catabolism and complement activation, which are relevant to GBS. Expert opinion: There is an unmet need for more effective immune therapies for GBS. New immunomodulatory therapies under development may provide more potent options for GBS patients who do not respond to IVIg or PE. Future directions may include incorporating neuroprotective interventions based on evolving understanding of mechanisms underlying nerve injury and axonal degeneration.Keywords
Funding Information
- GBS Foundation International (Discovery Award)
This publication has 20 references indexed in Scilit:
- Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trialThe Lancet Neurology, 2021
- Next-generation Fc receptor–targeting biologics for autoimmune diseasesAutoimmunity Reviews, 2019
- Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trialThe Lancet Neurology, 2018
- IgG-degrading enzyme of Streptococcus pyogenes (IdeS) prevents disease progression and facilitates improvement in a rabbit model of Guillain-Barré syndromeExperimental Neurology, 2017
- Sialylated intravenous immunoglobulin suppress anti-ganglioside antibody mediated nerve injuryExperimental Neurology, 2016
- Axon Self-Destruction: New Links among SARM1, MAPKs, and NAD+ MetabolismNeuron, 2016
- Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRsProceedings of the National Academy of Sciences, 2015
- Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activityProceedings of the National Academy of Sciences, 2015
- Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine modelBrain, 2008
- Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndromeThe Lancet, 1997